NCT05679284 A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
| NCT ID | NCT05679284 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tampere University Hospital |
| Condition | Drug Abuse, Intravenous |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-05-25 |
| Primary Completion | 2027-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-05-25 with a primary completion date of 2027-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In addition to the well-known toxicological harms of intravenous drug (IVD) use, there can also be local tissue complications, including infections, venous sclerosis, tissue necrosis, and drug needle fragment retentions. Drug needle fragments in subcutaneous tissue may cause local symptoms (usually pain and infections), but they have also been identified as causing emboli to organs. The literature has described numerous case reports of people who inject drugs (PWIDs) and have retained needle fragments. The prevalence of the condition is not known, and the researchers therefore aim to perform the first cross-sectional study of PWIDs to estimate how common needle fragment retentions are and what their risk factors are in this population.
Eligibility Criteria
Inclusion Criteria: * History of intravenous drug use * Current treatment of the drug abuse problem at a local low-threshold drug abuse service unit or primary health care centre. * Adherence to fill in the questionnaire * Participation to X-ray imaging of injection sites Exclusion Criteria: * No history of intravenous drug use * Does not adhere to fill in the questionnaire or refuses X-ray imaging * Pregnancy * Underage (18 years old)
Contact & Investigator
Otso Arponen, MD-PhD
STUDY CHAIR
Pirkanmaa Hospital District (PSHP)
Frequently Asked Questions
Who can join the NCT05679284 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Drug Abuse, Intravenous. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05679284 currently recruiting?
Yes, NCT05679284 is actively recruiting participants. Contact the research team at otso.arponen@tuni.fi for enrollment information.
Where is the NCT05679284 trial being conducted?
This trial is being conducted at Tampere, Finland.
Who is sponsoring the NCT05679284 clinical trial?
NCT05679284 is sponsored by Tampere University Hospital. The principal investigator is Otso Arponen, MD-PhD at Pirkanmaa Hospital District (PSHP). The trial plans to enroll 100 participants.